PT88115A - Dna constructs containing a kluyveromyces alpha-factor leader sequence for directing secretion of heterologous polypetides - Google Patents

Dna constructs containing a kluyveromyces alpha-factor leader sequence for directing secretion of heterologous polypetides

Info

Publication number: PT88115A
Authority: PT; Portugal
Prior art keywords: heterologous; factor leader; leader sequence; polypetides; dna constructs
Prior art date: 1987-07-28

Application number

PT88115A

Other languages

English (en)

Other versions

PT88115B (pt

Inventor

Anthony J Brake

Johannes A Van Den Berg

Original Assignee

Gist Brocades Nv

Chiron Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-07-28

Filing date

1988-07-27

Publication date

1989-06-30

1988-07-27 Application filed by Gist Brocades Nv, Chiron Corp filed Critical Gist Brocades Nv

1989-06-30 Publication of PT88115A publication Critical patent/PT88115A/pt

1995-03-01 Publication of PT88115B publication Critical patent/PT88115B/pt

Links

IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 title abstract 3
241000235649 Kluyveromyces Species 0.000 title abstract 2
230000028327 secretion Effects 0.000 title 1
240000004808 Saccharomyces cerevisiae Species 0.000 abstract 2
229920001184 polypeptide Polymers 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
108020004414 DNA Proteins 0.000 abstract 1
241001138401 Kluyveromyces lactis Species 0.000 abstract 1
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
108010064037 prorennin Proteins 0.000 abstract 1
230000003248 secreting effect Effects 0.000 abstract 1
125000006850 spacer group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6478—Aspartic endopeptidases (3.4.23)
- C12N9/6481—Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Mycology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Saccharide Compounds (AREA)
Peptides Or Proteins (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PT88115A 1987-07-28 1988-07-27 Processo para a preparacao de construcoes de adn que contem uma sequencia guia do factor de kluyveromyces, de vectores de expressao que contem estas construcoes e de polipeptideos codificados por este adn PT88115B (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/078,551 US5010182A (en)	1987-07-28	1987-07-28	DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides

Publications (2)

Publication Number	Publication Date
PT88115A true PT88115A (pt)	1989-06-30
PT88115B PT88115B (pt)	1995-03-01

Family

ID=22144759

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT88115A PT88115B (pt)	1987-07-28	1988-07-27	Processo para a preparacao de construcoes de adn que contem uma sequencia guia do factor de kluyveromyces, de vectores de expressao que contem estas construcoes e de polipeptideos codificados por este adn

Country Status (19)

Country	Link
US (1)	US5010182A (pt)
EP (1)	EP0301669B1 (pt)
JP (1)	JP2680054B2 (pt)
KR (1)	KR970004940B1 (pt)
CN (1)	CN1045620C (pt)
AT (1)	ATE90727T1 (pt)
AU (1)	AU623860B2 (pt)
CA (1)	CA1327762C (pt)
DE (1)	DE3881776T2 (pt)
DK (1)	DK175365B1 (pt)
ES (1)	ES2058238T3 (pt)
FI (1)	FI101232B1 (pt)
HU (1)	HU213015B (pt)
IE (1)	IE62261B1 (pt)
IL (1)	IL87255A (pt)
NO (1)	NO180381C (pt)
NZ (1)	NZ225596A (pt)
PT (1)	PT88115B (pt)
ZA (1)	ZA885535B (pt)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1340772C (en)	1987-12-30	1999-09-28	Patricia Tekamp-Olson	Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
EP0394409B1 (en)	1988-09-02	1997-06-11	The Rockefeller University	Macrophage-derived inflammatory mediator (mip-2)
GB9015825D0 (en) *	1990-07-18	1990-09-05	Ciba Geigy Ag	In vitro processing of fusion proteins
AU5013893A (en) *	1992-08-14	1994-03-15	Rockefeller University, The	Herpesviral defective vector with rat preproenkephalin gene promoter
ZA954983B (en) *	1994-06-17	1996-02-14	Novo Nordisk As	N-terminally extended proteins expressed in yeast
US6500645B1 (en)	1994-06-17	2002-12-31	Novo Nordisk A/S	N-terminally extended proteins expressed in yeast
US6030945A (en) *	1996-01-09	2000-02-29	Genentech, Inc.	Apo-2 ligand
US6046048A (en) *	1996-01-09	2000-04-04	Genetech, Inc.	Apo-2 ligand
US6998116B1 (en)	1996-01-09	2006-02-14	Genentech, Inc.	Apo-2 ligand
US20050089958A1 (en) *	1996-01-09	2005-04-28	Genentech, Inc.	Apo-2 ligand
CA2249206A1 (en) *	1996-04-01	1997-10-09	Genentech, Inc.	Apo-2li and apo-3 apoptosis polypeptides
US20020165157A1 (en) *	1996-04-01	2002-11-07	Genentech, Inc.	Apo-2LI and Apo-3 polypeptides
US5851984A (en) *	1996-08-16	1998-12-22	Genentech, Inc.	Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) *	1996-08-16	2000-12-12	Genentech, Inc.	Uses of Wnt polypeptides
US6462176B1 (en)	1996-09-23	2002-10-08	Genentech, Inc.	Apo-3 polypeptide
US20020102706A1 (en) *	1997-06-18	2002-08-01	Genentech, Inc.	Apo-2DcR
WO2000039297A2 (en)	1998-12-23	2000-07-06	Genentech, Inc.	Il-1 related polypeptides
US6265186B1 (en)	1997-04-11	2001-07-24	Dsm N.V.	Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal RNA encoding domain, particularly with Kluyveromyces
US20100152426A1 (en) *	1997-05-15	2010-06-17	Ashkenazi Avi J	Apo-2 receptor fusion proteins
EP0981618B2 (en) *	1997-05-15	2011-08-24	Genentech, Inc.	Anti-apo-2 antibody
US6342369B1 (en) *	1997-05-15	2002-01-29	Genentech, Inc.	Apo-2-receptor
CA2293724C (en)	1997-06-05	2010-02-02	Xiaodong Wang	Apaf-1, the ced-4 human homolog, an activator of caspase-3
EP2083079A1 (en)	1997-06-18	2009-07-29	Genentech, Inc.	Apo-2DcR
ES2331900T3 (es) *	1997-08-26	2010-01-19	Genentech, Inc.	Receptor rtd.
US20030175856A1 (en) *	1997-08-26	2003-09-18	Genetech, Inc.	Rtd receptor
US20040231011A1 (en) *	2001-06-28	2004-11-18	Genentech, Inc.	DcR3 polypeptide, a TNFR homolog
WO1999014330A1 (en)	1997-09-18	1999-03-25	Genentech, Inc.	DcR3 POLYPEPTIDE, A TNFR HOMOLOG
EP1021542B1 (en)	1997-10-10	2009-03-04	Genentech, Inc.	Apo-3 ligand
ATE409225T1 (de)	1997-10-29	2008-10-15	Genentech Inc	Durch wnt-1 induzierbare gene
EP2014770A3 (en)	1997-10-29	2009-02-18	Genentech, Inc.	WNT-1 Iinduced secreted polypeptide WISP-2
ES2288649T3 (es)	1997-11-21	2008-01-16	Genentech, Inc.	Antigenos tipo a-33 y sus utilizaciones farmacologicas.
US7192589B2 (en)	1998-09-16	2007-03-20	Genentech, Inc.	Treatment of inflammatory disorders with STIgMA immunoadhesins
US6740739B1 (en)	1998-01-15	2004-05-25	Genentech, Inc.	Substitutional variants of APO-2 ligand
US6727079B1 (en) *	1998-02-25	2004-04-27	The United States Of America As Represented By The Department Of Health And Human Services	cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
NZ525914A (en)	1998-03-10	2004-03-26	Genentech Inc	Novel polypeptides and nucleic acids encoding the same
DE69939374D1 (de)	1998-03-17	2008-10-02	Genentech Inc	Zu vegf und bmp1 homologe polypeptide
NZ508878A (en)	1998-05-15	2003-08-29	Genentech Inc	IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells
EP1865061A3 (en)	1998-05-15	2007-12-19	Genentech, Inc.	IL-17 homologous polypeptides and therapeutic uses thereof
EP3112468A1 (en)	1998-05-15	2017-01-04	Genentech, Inc.	Il-17 homologous polypeptides and therapeutic uses thereof
EP2058334B1 (en) *	1998-06-12	2012-10-31	Genentech, Inc.	Monoclonal antibodies, cross-reactive antibodies and method for producing the same
US20020172678A1 (en)	2000-06-23	2002-11-21	Napoleone Ferrara	EG-VEGF nucleic acids and polypeptides and methods of use
EP1978029A3 (en)	1999-06-15	2008-10-15	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids endoding the same
NZ531141A (en)	1999-10-20	2005-07-29	Genentech Inc	Modulation of T cell differentiation for the treatment of T helper cell mediated diseases
EP1672070A3 (en)	1999-12-01	2006-10-04	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
DK1897944T3 (da)	1999-12-23	2011-10-24	Genentech Inc	IL-17 homologe polypeptider og terapeutisk anvendelse deraf
ATE288493T1 (de)	1999-12-30	2005-02-15	Genencor Int	Trichoderma reesei xylanase
CA2397207C (en) *	2000-01-13	2013-12-03	Genentech, Inc.	Novel stra6 polypeptides
DE60124080T2 (de) *	2000-03-23	2007-03-01	Elan Pharmaceuticals, Inc., San Francisco	Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
US6992081B2 (en)	2000-03-23	2006-01-31	Elan Pharmaceuticals, Inc.	Compounds to treat Alzheimer's disease
CA2403842C (en) *	2000-03-24	2012-09-25	Genencor International, Inc.	Increased production of secreted proteins by recombinant eukaryotic cells
CA2648048A1 (en)	2000-06-23	2002-01-03	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2275549A1 (en)	2000-06-23	2011-01-19	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP1299352B1 (en) *	2000-06-30	2005-12-28	Elan Pharmaceuticals, Inc.	Compounds to treat alzheimer's disease
US20030096864A1 (en) *	2000-06-30	2003-05-22	Fang Lawrence Y.	Compounds to treat alzheimer's disease
PE20020276A1 (es)	2000-06-30	2002-04-06	Elan Pharm Inc	COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en)	2000-06-30	2005-01-25	Pharmacia & Upjohn Company	Compounds to treat alzheimer's disease
EP2014298A3 (en)	2000-08-24	2009-10-07	Genentech, Inc.	Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
EP1944317A3 (en)	2000-09-01	2008-09-17	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en)	2000-10-27	2004-01-06	Genentech, Inc.	Identification and modification of immunodominant epitopes in polypeptides
US20070160576A1 (en)	2001-06-05	2007-07-12	Genentech, Inc.	IL-17A/F heterologous polypeptides and therapeutic uses thereof
CA2633171C (en)	2001-06-20	2012-11-20	Genentech, Inc.	Antibodies against tumor-associated antigenic target (tat) polypeptides
EP1401452A1 (en) *	2001-06-27	2004-03-31	Elan Pharmaceuticals, Inc.	Beta-hydroxyamine derivatives useful in the treatment of alzheimer's disease
PL368972A1 (en)	2001-08-29	2005-04-04	Genentech, Inc.	Bv8 nucleic acids and polypeptides with mitogenic activity
EP1487877B1 (en)	2001-09-18	2010-10-27	Genentech, Inc.	Compositions and methods for the diagnosis of tumors
WO2003088808A2 (en)	2002-04-16	2003-10-30	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
NZ533933A (en)	2002-01-02	2008-06-30	Genentech Inc	Compositions and methods for the diagnosis and treatment of glioma tumor
EP2388265A1 (en)	2002-02-22	2011-11-23	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
EP2305710A3 (en)	2002-06-03	2013-05-29	Genentech, Inc.	Synthetic antibody phage libraries
MXPA04012243A (es) *	2002-06-07	2005-02-25	Genentech Inc	Composiciones y metodos para l diagnostico y tratamiento de tumores.
EP2332956A1 (en)	2002-07-08	2011-06-15	Genentech, Inc.	Antibody binding to PRO71238
EP2116551A1 (en)	2002-09-11	2009-11-11	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
US20040121370A1 (en)	2002-09-11	2004-06-24	Genentech, Inc.	Novel composition and methods for the treatment of immune related diseases
WO2004024097A2 (en)	2002-09-16	2004-03-25	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
AU2003279084A1 (en)	2002-09-25	2004-04-19	Genentech, Inc.	Novel compositions and methods for the treatment of psoriasis
US20070185017A1 (en)	2002-10-29	2007-08-09	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
JP2006516094A (ja)	2002-11-08	2006-06-22	ジェネンテック・インコーポレーテッド	ナチュラルキラー細胞関連疾患の治療のための組成物と方法
EP1572116A4 (en)	2002-11-26	2007-12-12	Genentech Inc	COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
ATE494367T1 (de)	2002-12-18	2011-01-15	Hoffmann La Roche	Rekombinante desoxyribonuclease i aus rinder- pankreas mit hoher spezifischer aktivität
JP4912144B2 (ja)	2003-03-12	2012-04-11	ジェネンテック，インコーポレイテッド	造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
CN1798575A (zh)	2003-04-04	2006-07-05	健泰科生物技术公司	高浓度抗体和蛋白制剂
MXPA05013565A (es)	2003-06-12	2006-03-09	Lilly Co Eli	Proteinas de fusion analogas al glp-1.
PL2784084T5 (pl)	2003-07-08	2024-12-02	Novartis Pharma Ag	Przeciwciała antagonistyczne heterologicznych polipeptydów il-17a/f
WO2005019258A2 (en)	2003-08-11	2005-03-03	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
DE10342794A1 (de) *	2003-09-16	2005-04-21	Basf Ag	Sekretion von Proteinen aus Hefen
SI2295073T1 (sl)	2003-11-17	2014-07-31	Genentech, Inc.	Protitelo proti CD22 za zdravljenje tumorja hematopoetskega izvora
AU2004305075A1 (en) *	2003-12-19	2005-07-07	The Regents Of The University Of California	Methods and materials for assessing prostate cancer therapies
NZ550102A (en) *	2004-02-24	2010-10-29	Univ California	Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
US7709517B2 (en)	2005-05-13	2010-05-04	The Regents Of The University Of California	Diarylhydantoin compounds
CA2610709A1 (en)	2005-06-06	2006-12-14	Genentech, Inc.	Transgenic models for different genes and their use for gene characterization
US7931902B2 (en)	2005-08-15	2011-04-26	Genentech, Inc.	Gene disruptions, compositions and methods relating thereto
BRPI0617688A2 (pt) *	2005-10-21	2011-06-07	Hoffmann La Roche	método para expressão recombinante de um polipeptìdeo
WO2007081608A2 (en)	2005-11-21	2007-07-19	Genentech, Inc.	Novel gene disruptions, compositions and methods relating thereto
DE602005023550D1 (de)	2005-12-14	2010-10-21	Licentia Ltd	Verwendungen eines neurotrophischen Faktors
US20080311107A1 (en)	2006-02-17	2008-12-18	Genetech, Inc.	Novel Gene Disruptions, Compositions and Methods Relating Thereto
LT2656842T (lt)	2006-03-27	2016-09-26	The Regents Of The University Of California	Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
KR101456722B1 (ko) *	2006-03-29	2014-10-31	더 리전트 오브 더 유니버시티 오브 캘리포니아	디아릴티오히단토인 화합물
WO2007126455A2 (en)	2006-04-05	2007-11-08	Genentech, Inc.	Method for using boc/cdo to modulate hedgehog signaling
EP2082645A1 (en)	2006-04-19	2009-07-29	Genentech, Inc.	Novel gene disruptions, compositions and methods relating thereto
CA2662610A1 (en) *	2006-10-24	2008-05-02	Novozymes A/S	Improved alpha factor signal peptide for producing a polypeptide
CA2668208C (en)	2006-11-02	2017-09-12	Daniel J. Capon	Hybrid immunoglobulins with moving parts
CA2676790A1 (en)	2007-02-22	2008-08-28	Genentech, Inc.	Methods for detecting inflammatory bowel disease
DK2474557T3 (da)	2007-07-16	2014-11-10	Genentech Inc	Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
NZ583318A (en)	2007-07-16	2012-07-27	Genentech Inc	Humanized anti-cd79b antibodies and immunoconjugates and methods of use
CN101361968B (zh)	2007-08-06	2011-08-03	健能隆医药技术（上海）有限公司	白介素-22在治疗脂肪肝中的应用
JP5642549B2 (ja)	2007-10-12	2014-12-17	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	複数の核酸からのタンパク質発現
TWI469971B (zh)	2007-10-26	2015-01-21	Univ California	二芳基乙內醯脲類化合物
SG187517A1 (en)	2008-01-31	2013-02-28	Genentech Inc	Anti-cd79b antibodies and immunoconjugates and methods of use
EP3208612B1 (en)	2008-04-09	2019-09-18	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
CR20170001A (es)	2008-04-28	2017-08-10	Genentech Inc	Anticuerpos anti factor d humanizados
FI20080326A0 (fi)	2008-04-30	2008-04-30	Licentia Oy	Neurotroofinen tekijä MANF ja sen käytöt
WO2010120561A1 (en)	2009-04-01	2010-10-21	Genentech, Inc.	Anti-fcrh5 antibodies and immunoconjugates and methods of use
EP2258855A1 (en)	2009-05-28	2010-12-08	Universität für Bodenkultur Wien	Expression sequences
MX368790B (es) *	2009-10-15	2019-10-16	Genentech Inc	Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada.
US8697386B2 (en)	2009-10-22	2014-04-15	Genentech, Inc.	Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011056494A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor type iib compositions and methods of use
WO2011056502A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Bone morphogenetic protein receptor type ii compositions and methods of use
KR20120103587A (ko)	2009-11-12	2012-09-19	제넨테크, 인크.	수상돌기 소극 밀도를 증진시키는 방법
BR112012012750A2 (pt)	2009-11-30	2020-08-11	Genentech Inc	anticorpo isolado, célula, ácido nucleíco isolado e método
WO2011103202A2 (en)	2010-02-16	2011-08-25	Aragon Pharmaceuticals, Inc.	Androgen receptor modulators and uses thereof
TWI429453B (zh)	2010-02-23	2014-03-11	建南德克公司	抗tat419抗體及其用途
MX342239B (es)	2010-05-03	2016-09-21	Genentech Inc *	Composiciones y metodos para el diagnostico y tratamiento de tumores.
EP2585094B1 (en)	2010-06-25	2018-08-01	INSERM - Institut National de la Santé et de la Recherche Médicale	Flagellin polypeptide as tlr5 agonist for use in the treatment of respiratory tract infections
CN102380091A (zh)	2010-08-31	2012-03-21	健能隆医药技术（上海）有限公司	白介素-22在治疗病毒性肝炎中的应用
AU2011302522A1 (en)	2010-09-15	2013-05-02	Aligna Technologies, Inc.	Bioproduction of aromatic chemicals from lignin-derived compounds
CN103946236B (zh)	2011-11-23	2018-02-16	弗·哈夫曼-拉罗切有限公司	表达cd40l的哺乳动物细胞及其用途
JP6224077B2 (ja)	2012-04-17	2017-11-01	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	改変された核酸を用いてポリペプチドを発現させるための方法
SG11201501870RA (en)	2012-09-26	2015-04-29	Aragon Pharmaceuticals Inc	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
AU2013341049B2 (en)	2012-10-29	2017-07-20	Lonza Ltd	Expression sequences
EP2929022B1 (en)	2012-12-07	2016-11-09	Danisco US Inc.	Compositions and methods of use
WO2014088940A1 (en)	2012-12-07	2014-06-12	Danisco Us Inc.	Compositions and methods of use
SG10201907684PA (en)	2013-01-15	2019-10-30	Aragon Pharmaceuticals Inc	Androgen receptor modulator and uses thereof
EP3385277A1 (en)	2013-03-15	2018-10-10	F. Hoffmann-La Roche AG	Il-22 polypeptides and il-22 fc fusion proteins and methods of use
US11220556B2 (en)	2013-03-15	2022-01-11	Biomolecular Holdings Llc	Hybrid immunoglobulin containing non-peptidyl linkage
US20160075766A1 (en)	2013-05-21	2016-03-17	Roche Diagnostics Operations, Inc.	Method for producing antibodies using ovine b-cells and uses thereof
CN104623637A (zh)	2013-11-07	2015-05-20	健能隆医药技术（上海）有限公司	Il-22二聚体在制备静脉注射药物中的应用
NZ724904A (en)	2014-03-14	2023-04-28	Biomolecular Holdings Llc	Hybrid immunoglobulin containing non-peptidyl linkage
WO2016054176A1 (en)	2014-09-30	2016-04-07	Danisco Us Inc	Compositions comprising beta-mannanase and methods of use
WO2016054205A1 (en)	2014-09-30	2016-04-07	Danisco Us Inc	Compositions comprising beta mannanase and methods of use
WO2016054168A1 (en)	2014-09-30	2016-04-07	Danisco Us Inc	Compositions comprising beta mannanase and methods of use
US20170218351A1 (en)	2014-09-30	2017-08-03	Danisco Us Inc.	Compositions comprising beta-mannanase and methods of use
EP3201334A1 (en)	2014-09-30	2017-08-09	Danisco US Inc.	Compositions comprising beta-mannanase and methods of use
US20180002683A1 (en)	2014-12-18	2018-01-04	Danisco Us Inc.	Engineered multifunctional enzymes and methods of use
WO2016100837A1 (en)	2014-12-18	2016-06-23	Danisco Us Inc	Engineered multifunctional enzymes and methods of use
TWI726969B (zh)	2016-01-11	2021-05-11	比利時商健生藥品公司	用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
WO2017167714A1 (en)	2016-03-30	2017-10-05	F. Hoffmann-La Roche Ag	B-cell cultivation method
WO2017181143A1 (en)	2016-04-15	2017-10-19	Generon (Shanghai) Corporation, Ltd.	Use of il-22 in treating necrotizing enterocolitis
JP6916884B2 (ja)	2017-01-02	2021-08-11	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｂ細胞培養法
WO2018152496A1 (en)	2017-02-17	2018-08-23	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Compositions and methods for the diagnosis and treatment of zika virus infection
EP4230649A3 (en)	2017-04-25	2023-10-25	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
CN110621773B (zh)	2017-05-19	2023-06-09	豪夫迈·罗氏有限公司	用于产生胸腺细胞上清液的方法
CN109022478A (zh) *	2017-06-09	2018-12-18	康码（上海）生物科技有限公司	一种用于高通量体外蛋白质合成的dna元件
US11827669B2 (en)	2017-07-19	2023-11-28	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
AU2018351714A1 (en)	2017-10-16	2020-04-30	Aragon Pharmaceuticals, Inc.	Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
BR112020015016A2 (pt)	2018-01-26	2020-12-29	Genentech, Inc.	Composições farmacêuticas, métodos de tratamento da doença inflamatória intestinal, de inibição da infecção microbiana no intestino e de aceleração ou melhora da cicatrização de feridas
AU2019212709A1 (en)	2018-01-26	2020-08-13	Genentech, Inc.	IL-22 Fc fusion proteins and methods of use
JP2021514354A (ja)	2018-02-21	2021-06-10	ジェネンテック，インコーポレイテッド	ＩＬ−２２Ｆｃ融合タンパク質による治療のための投与
WO2019213416A1 (en)	2018-05-02	2019-11-07	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
EP3990484A1 (en)	2019-06-28	2022-05-04	F. Hoffmann-La Roche AG	Method for the production of an antibody
EP4106794A4 (en)	2020-02-19	2024-03-20	Evive Biotechnology (Shanghai) Ltd	METHOD FOR TREATING TRANSPLANT AND HOST DISEASE
WO2021207662A1 (en)	2020-04-10	2021-10-14	Genentech, Inc.	Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
AU2023330110A1 (en)	2022-08-22	2025-03-06	Abdera Therapeutics Inc.	Dll3 binding molecules and uses thereof
WO2026009000A1 (en)	2024-07-04	2026-01-08	Solasta Bio Limited	Methods for production of insecticidal neuropeptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3382547D1 (de) *	1983-01-12	1992-05-27	Chiron Corp	Sekretorische expression in eukaryoten.
NZ207926A (en) *	1983-04-25	1988-04-29	Genentech Inc	Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
AU2722184A (en) *	1983-04-25	1984-11-01	Genentech Inc.	Use of alpha sequences in yeast expression systems
JPS6156078A (ja) *	1984-07-27	1986-03-20	Suntory Ltd	酵母を宿主とする分泌発現ベクタ−
NO302485B1 (no) *	1987-07-28	1998-03-09	Gist Brocades Bv	Fremgangsmåte for fremstilling av et polypeptid av interesse i en Klyveromyces vertscelle, transformert Klyveromyces vertscelle og anvendelse derav, plasmid og DNA konstruksjon
CA1340772C (en) *	1987-12-30	1999-09-28	Patricia Tekamp-Olson	Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences

1987
- 1987-07-28 US US07/078,551 patent/US5010182A/en not_active Expired - Lifetime
1988
- 1988-07-27 PT PT88115A patent/PT88115B/pt not_active IP Right Cessation
- 1988-07-28 EP EP88201631A patent/EP0301669B1/en not_active Expired - Lifetime
- 1988-07-28 AT AT88201631T patent/ATE90727T1/de not_active IP Right Cessation
- 1988-07-28 NO NO883346A patent/NO180381C/no not_active IP Right Cessation
- 1988-07-28 CN CN88104680A patent/CN1045620C/zh not_active Expired - Lifetime
- 1988-07-28 JP JP63189552A patent/JP2680054B2/ja not_active Expired - Lifetime
- 1988-07-28 CA CA000573342A patent/CA1327762C/en not_active Expired - Lifetime
- 1988-07-28 NZ NZ225596A patent/NZ225596A/en unknown
- 1988-07-28 AU AU20136/88A patent/AU623860B2/en not_active Expired
- 1988-07-28 ZA ZA885535A patent/ZA885535B/xx unknown
- 1988-07-28 DK DK198804222A patent/DK175365B1/da not_active IP Right Cessation
- 1988-07-28 KR KR1019880009541A patent/KR970004940B1/ko not_active Expired - Fee Related
- 1988-07-28 IE IE231388A patent/IE62261B1/en not_active IP Right Cessation
- 1988-07-28 DE DE88201631T patent/DE3881776T2/de not_active Expired - Lifetime
- 1988-07-28 ES ES88201631T patent/ES2058238T3/es not_active Expired - Lifetime
- 1988-07-28 HU HU884021A patent/HU213015B/hu unknown
- 1988-07-28 IL IL87255A patent/IL87255A/xx not_active IP Right Cessation
- 1988-07-28 FI FI883541A patent/FI101232B1/fi active IP Right Grant

Also Published As

Publication number	Publication date
IE62261B1 (en)	1995-01-11
DE3881776D1 (de)	1993-07-22
FI101232B (fi)	1998-05-15
IL87255A0 (en)	1988-12-30
FI101232B1 (fi)	1998-05-15
NO180381B (no)	1996-12-30
JP2680054B2 (ja)	1997-11-19
ATE90727T1 (de)	1993-07-15
CN1032367A (zh)	1989-04-12
AU623860B2 (en)	1992-05-28
KR970004940B1 (ko)	1997-04-10
NO883346L (no)	1989-01-30
HU213015B (en)	1997-01-28
AU2013688A (en)	1989-02-02
DK422288A (da)	1989-01-29
NZ225596A (en)	1991-04-26
EP0301669A1 (en)	1989-02-01
IL87255A (en)	1993-04-04
ZA885535B (en)	1989-04-26
KR890002406A (ko)	1989-04-10
DK422288D0 (da)	1988-07-28
PT88115B (pt)	1995-03-01
EP0301669B1 (en)	1993-06-16
US5010182A (en)	1991-04-23
FI883541L (fi)	1989-01-29
JPH01124390A (ja)	1989-05-17
HUT47638A (en)	1989-03-28
DE3881776T2 (de)	1993-11-18
ES2058238T3 (es)	1994-11-01
NO180381C (no)	1997-04-09
DK175365B1 (da)	2004-09-13
CA1327762C (en)	1994-03-15
IE882313L (en)	1989-01-28
CN1045620C (zh)	1999-10-13
FI883541A0 (fi)	1988-07-28
NO883346D0 (no)	1988-07-28

Legal Events

Date	Code	Title	Description
1995-03-01	FG3A	Patent granted, date of granting	Effective date: 19940809
1999-07-30	PC3A	Transfer or assignment	Free format text: 19990329 DSM N.V. NL
2005-10-31	PC3A	Transfer or assignment	Owner name: DSM IP ASSETS B. V., NL Effective date: 20050823
2008-02-27	PD4A	Change of proprietorship	Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC., US Effective date: 20080215
2009-08-17	MM4A	Annulment/lapse due to non-payment of fees, searched and examined patent	Free format text: MAXIMUM VALIDITY LIMIT REACHED Effective date: 20090809

Publication	Publication Date	Title
PT88115A (pt)	1989-06-30	Dna constructs containing a kluyveromyces alpha-factor leader sequence for directing secretion of heterologous polypetides
EP0396612A4 (en)	1991-10-02	Novel plasmid vector with pectate lyase signal sequence
FI901428A0 (fi)	1990-03-21	Peptid och dna-sekvenser.
IE820069L (en)	1983-06-01	Recombinant dna encoding a polypeptide
IL87366A (en)	1993-08-18	Decay-accelerating factor (daf) polypeptide dna fusions to dna encoding heterologous polypeptides, host cells transformed with daf fusion dna, and daf fusion proteins
DE3382760D1 (de)	1994-11-17	Herstellung von funktionellen menschlichen Urokinasepolypeptiden.
ES8802440A1 (es)	1988-06-01	Un metodo para preparar una particula que puede ser empleada como vacuna contra la infeccion por hepatitis b
DK595286A (da)	1987-06-13	Fremgangsmaade til fremstilling af thrombininhibitorer
ATA192895A (de)	1998-07-15	Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
DE3884565D1 (de)	1993-11-04	Hefe-expressionssystem.
ES2080759T3 (es)	1996-02-16	Produccion de proteinas o polipeptidos fusionados.
DK260188D0 (da)	1988-05-11	Enzymproduktion
FI861559L (fi)	1986-10-16	Menetelmä hepatitis B-viruksen pinta-antigeenin PreS1-PreS2-S-proteiinin koodaavan alueen koodaamia proteiineja käsittävän proteiinin valmistamiseksi sekä menetelmässä käytettävät yhdistelmä-DNA-vektorit ja -kontameerit sekä nisäkässolut
FI934079L (fi)	1993-09-17	Menetelmä fuusioproteiinin valmistamiseksi